RETEVMO: payments to doctors
Payments that named RETEVMO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.5M
- Providers
- 8,037
- Transactions
- 28,175
- Average per transaction
- $54
The per-transaction average — $54 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,037 providers the average total is $190, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Lilly USA, LLC | $1,427,716 | 93.5% |
| Eli Lilly | $57,901 | 3.8% |
| Eli Lilly Export S.A. Puerto Rico Branch | $42,003 | 2.7% |